Peptide Company Owner Sentenced to Nearly Six Years for Selling Steroid-Laced Supplements to 54,000 Customers

The owner of Paradigm Peptides has been sentenced to nearly six years in prison after deliberately selling unapproved medicines laced with testosterone to approximately 54,000 customers across 80 countries. Matthew Kawa admitted to importing products from China and India while falsely claiming they were manufactured in the United States and had undergone rigorous third-party testing. The case represents the largest criminal enforcement action against a peptide vendor in what regulators describe as a largely unregulated marketplace.

The Deception Behind the Business

Paradigm Peptides operated with an elaborate scheme to mask the true origins and contents of its products. Despite advertising on its website that all items underwent "stringent" testing to ensure efficacy, purity and potency, Kawa and his sister Jennifer Stechkober—who also pleaded guilty—admitted they never tested or analysed any products. The pair forged laboratory certificates of analysis, the documents that manufacturers use to certify safety and quality. When federal investigators tested six compounds sold as testosterone alternatives, all contained actual testosterone, a steroid hormone subject to strict medical regulation.

Real-World Harm and Health Consequences

One customer, Daniel Murphy, experienced severe psychiatric effects after unknowingly consuming testosterone for two years. His mental health deteriorated to the point of psychosis, during which he believed his wife was attempting to steal his business and his mother-in-law posed a mortal threat. This case exemplifies the dangers highlighted by prosecutors, who noted that synthetic testosterone can cause liver damage, serious psychiatric effects, heart and respiratory problems, infertility in men and increased risk of testicular cancer when taken without medical supervision. During sentencing, U.S. District Court Judge Cristal Brisco stated that Kawa ignored "numerous warnings" from regulators and left "an incredible trail of harm."

Sentencing and Regulatory Impact

Kawa, 48, was sentenced to 70 months in prison and ordered to forfeit $5 million in business proceeds. His sister received 16 months. The case underscores the explosive growth of the unregulated peptide market, which has expanded dramatically into mainstream consumer awareness over recent years. Peptides themselves—short chains of amino acids—have legitimate medical uses, including treatment for diabetes. However, the "research use only" disclaimer has become industry standard cover for products marketed directly to consumers seeking performance enhancement and other health benefits outside established medical channels. Paradigm Peptides was shut down in March 2024.